Business ❯ Pharmaceutical Industry ❯ Market Analysis

Sales Projections

Drug Pricing Eli Lilly Consumer Demand Blenrep Therapeutic Products Investment Opportunities Daraxonrasib Sales Drug Approval Process

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Unclear cardiovascular signals together with unfinished manufacturing checks could shape regulators' verdict on Lilly's application.

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree